Web30 mar 2024 · - As of year-end 2024, Sutro had cash and investments of $302.3 million and shares of Vaxcyte common stock valued at $32.0 million, which together provide a projected cash runway into the second half of 2024-. SOUTH SAN FRANCISCO, Calif., March 30, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the …
Sutro Biopharma, Inc. (STRO) Stock Price, News, Quote & History
Web10 feb 2024 · You can click the graphic below for the historical numbers, but it shows that Sutro Biopharma had US$19.3m of debt in September 2024, down from US$25.0m, one year before. But it also has US$324.2m in cash to offset that, meaning it has US$305.0m net cash. NasdaqGM:STRO Debt to Equity History February 10th 2024. Web1 giorno fa · Sutro Biopharma, Inc. (STRO) Stock Price, Quote & News - Stock Analysis Sutro Biopharma, Inc. ( STRO) NASDAQ: STRO · IEX Real-Time Price · USD 5.13 … cells within cells excel
Sutro Biopharma, Inc. (STRO) Stock Price, Quote & News
Web3 apr 2024 · Most relevant news about SUTRO BIOPHARMA, INC. Truist Securities Adjusts Sutro Biopharma's Price Target to $25 From $21, Keeps Buy Rat.. Transcript : Sutro Biopharma, Inc. Presents at 41st Annual J.P. Morgan Health.. Piper Sandler Adjusts Price Target on Sutro Biopharma to $18 From $16, Maintains Overwe.. Web21 mar 2024 · Sutro Biopharma Quant Rating and Wall St. Analysts rating both stands with Buy (5 Very Bullish, 3 Bullish). Since the start of 2024, Sutro Biopharma shares were … Web28 feb 2024 · Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference. SOUTH SAN FRANCISCO, Calif., March 1, 2024 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that … cells reference vba